Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 192

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 192
---
 $— $— $17,834 Financial Liabilities Measured at Amortized Cost:   2.125% convertible senior notes due 2029 (1)$280,721 $— $291,453 $—    Revolving Credit Facility$96,000 $— $96,000 $— (1) The closing price of the Company’s common stock as reported on the Nasdaq Global Select Market was $25.77 per share on September 30, 2025, compared to a conversion price of $39.56 per share. At September 30, 2025, as the conversion price was above the stock price, the requirements for conversion have not been met.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  22

Financial Assets and Liabilities Measured at Fair Value on a Recurring BasisEquity and Convertible Note InvestmentsThe Company holds strategic investments in clinical and preclinical stage privately-held biotechnology companies in the form of equity and convertible note investments. The following investments have no readily determinable fair value and are recorded at cost minus impairment, if any, plus or minus observable price changes of identical or similar investments (in thousands):Equity InvestmentsConvertible Notes ReceivableTotalBalance at December 31, 2023$15,877 $12,134 $28,011 Foreign currency adjustments— (236)(236)Balance at December 31, 202415,877 11,898 27,775 Purchases— 1,250 1,250 Impairments(4,000)(7,000)(11,000)Realized gain of prior investments (1)4,227 1,674 5,901 Settled investments (1)(8,315)(5,322)(13,637)Foreign currency adjustments(39)— (39)Balance at September 30, 2025$7,750 $2,500 $10,250 (1) In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable were part of the fair value of consideration exchanged. Upon acquiring the remaining 81% ownership interest in GQ Bio, the Company remeasured its previously held equity interest to its acquisition-date fair value. The $4.2 million gain resulting from the equity investment was recognized as other